This company listing is no longer active
ASLAN Pharmaceuticals Performance dei guadagni passati
Il passato criteri di controllo 0/6
ASLAN Pharmaceuticals's earnings have been declining at an average annual rate of -6.5%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 55.7% per year.
Informazioni chiave
-6.5%
Tasso di crescita degli utili
18.3%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 55.7% |
| Rendimento del capitale proprio | n/a |
| Margine netto | -291.9% |
| Ultimo aggiornamento sui guadagni | 31 Mar 2024 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Ripartizione dei ricavi e delle spese
Come ASLAN Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 24 | 12 | -35 | 13 | 34 |
| 31 Dec 23 | 12 | -44 | 13 | 42 |
| 30 Sep 23 | 12 | -45 | 13 | 44 |
| 30 Jun 23 | 12 | -46 | 12 | 44 |
| 31 Mar 23 | 0 | -58 | 11 | 43 |
| 31 Dec 22 | 0 | -51 | 10 | 38 |
| 30 Sep 22 | 0 | -46 | 9 | 36 |
| 30 Jun 22 | 0 | -45 | 10 | 34 |
| 31 Mar 22 | 0 | -38 | 11 | 28 |
| 31 Dec 21 | 0 | -31 | 12 | 22 |
| 30 Sep 21 | 0 | -28 | 13 | 16 |
| 30 Jun 21 | 0 | -21 | 11 | 13 |
| 31 Mar 21 | 0 | -20 | 9 | 11 |
| 31 Dec 20 | 0 | -16 | 7 | 9 |
| 30 Sep 20 | 0 | -40 | 7 | 9 |
| 30 Jun 20 | 0 | -41 | 7 | 11 |
| 31 Mar 20 | 0 | -47 | 7 | 15 |
| 31 Dec 19 | 3 | -47 | 9 | 17 |
| 30 Sep 19 | 3 | -27 | 7 | 22 |
| 30 Jun 19 | 3 | -34 | 9 | 27 |
| 31 Mar 19 | 3 | -37 | 10 | 30 |
| 31 Dec 18 | 0 | -42 | 11 | 32 |
| 30 Sep 18 | 0 | -45 | 11 | 34 |
| 30 Jun 18 | 0 | -41 | 11 | 31 |
| 31 Mar 18 | 0 | -42 | 10 | 31 |
| 31 Dec 17 | 0 | -41 | 9 | 31 |
| 30 Sep 17 | 1 | -33 | 9 | 25 |
| 30 Jun 17 | 12 | -19 | 8 | 22 |
| 31 Mar 17 | 12 | -14 | 8 | 18 |
| 31 Dec 16 | 11 | -9 | 7 | 13 |
| 30 Sep 16 | 11 | -7 | 8 | 8 |
| 30 Jun 16 | 0 | -15 | 7 | 7 |
| 31 Mar 16 | 0 | -15 | 7 | 7 |
| 31 Dec 15 | 0 | -14 | 7 | 6 |
Guadagni di qualità: ASLN is currently unprofitable.
Margine di profitto in crescita: ASLN is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ASLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerare la crescita: Unable to compare ASLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: ASLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Rendimento del capitale proprio
ROE elevato: ASLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.